Amit Joglekar, MD
Pulmonary Disease · Rochester, NHNPI 1891879045
Payments from drug & device makers
What this record shows
Medtronic accounts for 66.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $1,403 and has fallen 97.1% since, to $41 in 2025.
Across 52 payments — averaging $40.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- GSK$298
- Actelion Pharmaceuticals US, Inc.$97
- Harmony Biosciences LLC$80
- Mylan Specialty L.p.$80
- AstraZeneca$64
- plus $82 from 4 others
What the payments were for
- Travel & lodging$1,02348%
- Food & beverage$1,08852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $1,412 |
| GSK | 18 | $298 |
| Actelion Pharmaceuticals US, Inc. | 5 | $97 |
| Harmony Biosciences LLC | 4 | $80 |
| Mylan Specialty L.p. | 4 | $80 |
| AstraZeneca | 4 | $64 |
| Sanofi | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$1,271
How this compares
$2,111 in reported general payments places this provider in the 80th percentile of 78 pulmonary disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 20 | $227,530 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 171 | $140,801 |
| Breo ElliptaFluticasone/Vilanterol | 115 | $59,776 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $21,139 |
| Spiriva RespimatTiotropium Bromide | 37 | $20,803 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $17,612 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $11,142 |
| Arnuity ElliptaFluticasone Furoate | 46 | $10,213 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,826 |
| BreynaBudesonide/Formoterol Fumarate | 33 | $3,815 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 158 | $3,780 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $2,086 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,079 |
| Montelukast Sodium | 108 | $1,309 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $1,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $20 | $248,33357 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $298 | $233,227383 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $64 | $32,28182 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 78 pulmonary disease providers in New Hampshire.
Other pulmonary disease in Rochester
- Donald MahlerLebanon$411K
- Bianca MonteiroDover$43K
- Jeffrey StewartLebanon$30K
- Erik SwensonLebanon$29K
- Elliot BackerLebanon$24K
- H ParkerLebanon$13K
- Christopher DaigleNashua$12K
- Danilo AblanPortsmouth$10K
- Alex GiffordLebanon$8K
- Naim AounNashua$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.